Altretamine Dosage

Medically reviewed on August 4, 2017.

Usual Adult Dose for Ovarian Cancer

260 mg/m2/day orally given in 4 divided doses after meals and at bedtime, either for 14 or 21 consecutive days in a 28-day cycle.

Comments: There is no pharmacokinetic information supporting this dosing regimen and the effect of food on bioavailability and pharmacokinetics has not been evaluated.

Use: Indicated as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based combination.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

GI Intolerance Unresponsive to Symptomatic Measures; White Blood Count Less Than 2,000/mm3 or Granulocyte Count Less Than 1,000/mm3; Platelet Count Less Than 75,000/mm3; and/or Progressive Neurotoxicity:
-Temporarily discontinue treatment for 14 days or longer and subsequently restart dose at 200 mg/m2/day.
-Discontinue treatment indefinitely if neurological symptoms fail to stabilize on the reduced dose schedule.

Precautions

US BOXED WARNING:
-This drug should only be given under the supervision of a physician experienced in the use of antineoplastic agents.
-Peripheral blood counts should be monitored at least monthly, prior to the initiation of each treatment course and as clinical indicated.
-Neurological examination should be performed regularly during treatment because of the possibility of drug-related neurotoxicity.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration Advice:
-Preparation, handling, and disposal of this drug should be performed in a manner consistent with safe procedures for cytotoxic agents.

Storage Requirements:
-This drug should be stored up to 25 degrees Celsius (77 Fahrenheit).

General:
-This drug has been efficacious for certain ovarian tumors resistant to classical alkylating agents.
-This drug is practically insoluble in water but is increasingly soluble at pH3 and below.

Monitoring:
-Hematological: Peripheral blood counts
-Nervous System: Neurological examination

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer